ATE435207T1 - Pyridin-3-carbonsäureamidderivate als cb1-inverse agonisten - Google Patents
Pyridin-3-carbonsäureamidderivate als cb1-inverse agonistenInfo
- Publication number
- ATE435207T1 ATE435207T1 AT06725329T AT06725329T ATE435207T1 AT E435207 T1 ATE435207 T1 AT E435207T1 AT 06725329 T AT06725329 T AT 06725329T AT 06725329 T AT06725329 T AT 06725329T AT E435207 T1 ATE435207 T1 AT E435207T1
- Authority
- AT
- Austria
- Prior art keywords
- pyridine
- acid amide
- carbonic acid
- amide derivatives
- inverse agonists
- Prior art date
Links
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 238000003874 inverse correlation nuclear magnetic resonance spectroscopy Methods 0.000 title 1
- 235000001968 nicotinic acid Nutrition 0.000 title 1
- 239000011664 nicotinic acid Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05102709 | 2005-04-06 | ||
| PCT/EP2006/061060 WO2006106054A1 (en) | 2005-04-06 | 2006-03-27 | Pyridine-3-carboxamide derivatives as cb1 inverse agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE435207T1 true ATE435207T1 (de) | 2009-07-15 |
Family
ID=36525215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06725329T ATE435207T1 (de) | 2005-04-06 | 2006-03-27 | Pyridin-3-carbonsäureamidderivate als cb1-inverse agonisten |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7229999B2 (de) |
| EP (1) | EP1868999B1 (de) |
| JP (1) | JP4712865B2 (de) |
| KR (1) | KR100970050B1 (de) |
| CN (1) | CN101155781B (de) |
| AR (1) | AR054024A1 (de) |
| AT (1) | ATE435207T1 (de) |
| AU (1) | AU2006232662B2 (de) |
| BR (1) | BRPI0609685A2 (de) |
| CA (1) | CA2602787C (de) |
| DE (1) | DE602006007563D1 (de) |
| DK (1) | DK1868999T3 (de) |
| ES (1) | ES2326280T3 (de) |
| IL (1) | IL186126A0 (de) |
| MX (1) | MX2007012213A (de) |
| NO (1) | NO20075082L (de) |
| PL (1) | PL1868999T3 (de) |
| PT (1) | PT1868999E (de) |
| RU (1) | RU2404164C2 (de) |
| TW (1) | TWI300777B (de) |
| WO (1) | WO2006106054A1 (de) |
| ZA (1) | ZA200708491B (de) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004010207A1 (de) * | 2004-03-02 | 2005-09-15 | Aventis Pharma S.A. | Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate |
| DE102004010194A1 (de) * | 2004-03-02 | 2005-10-13 | Aventis Pharma Deutschland Gmbh | 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate, ihre Herstellung und Verwendung in Arzneimitteln |
| WO2007011760A2 (en) * | 2005-07-15 | 2007-01-25 | Kalypsys, Inc. | Inhibitors of mitotic kinesin |
| WO2007062459A1 (en) * | 2005-11-29 | 2007-06-07 | Cytopia Research Pty Ltd | Selective kinase inhibitors based on pyridine scaffold |
| US7629346B2 (en) | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
| EP2061767B1 (de) | 2006-08-08 | 2014-12-17 | Sanofi | Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung |
| US7781593B2 (en) | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
| KR101107896B1 (ko) | 2006-10-04 | 2012-01-25 | 에프. 호프만-라 로슈 아게 | 고 밀도 지단백질(ｈｄｌ)-콜레스테롤 상승제로서 3-피리딘카복스아마이드 및 2-피라진카복스아마이드 유도체 |
| CN101522644B (zh) * | 2006-10-04 | 2013-04-24 | 霍夫曼-拉罗奇有限公司 | 作为cb2受体调节剂的吡嗪-2-羧酰胺衍生物 |
| TW200827346A (en) | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
| TW200836719A (en) | 2007-02-12 | 2008-09-16 | Astrazeneca Ab | Chemical compounds |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2009054929A1 (en) * | 2007-10-23 | 2009-04-30 | Merck & Co., Inc. | Cannabinoid-1 receptor modulators useful for the treatment of alzheimer's disease |
| AU2009211215B2 (en) | 2008-02-04 | 2011-11-03 | Astrazeneca Ab | Novel crystalline forms of 4- [4- (2-adamantylcarbam0yl) -5-tert-butyl-pyrazol-1-yl] benzoic acid |
| US7897621B2 (en) | 2008-03-31 | 2011-03-01 | Hoffmann-La Roche Inc. | 2-trifluoromethylnicotinamide derivatives as HDL-cholesterol raising agents |
| US8088920B2 (en) | 2008-03-31 | 2012-01-03 | Hoffmann-La Roche Inc. | 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents |
| US8349876B2 (en) | 2008-05-19 | 2013-01-08 | The University Of Tennesee Research Foundation | Pyridine non-classical cannabinoid compounds and related methods of use |
| JP2011520974A (ja) | 2008-05-19 | 2011-07-21 | ユニヴァーシティ オブ テネシー リサーチ ファウンデーション，ザ | ピリミジンの古典的カンナビノイド化合物及び関連する使用方法 |
| US8541431B2 (en) * | 2008-05-19 | 2013-09-24 | The University Of Tennessee Research Foundation | Pyrimidine non-classical cannabinoid compounds and related methods of use |
| CA2724697A1 (en) * | 2008-05-19 | 2009-11-26 | University Of Tennessee Research Foundation, The | Pyridine classical cannabinoid compounds and related methods of use |
| US8476439B2 (en) | 2008-05-19 | 2013-07-02 | The University Of Tennessee Research Foundation | Pyridine classical cannabinoid compounds and related methods of use |
| US8158654B2 (en) * | 2008-05-19 | 2012-04-17 | The University Of Tennessee Research Foundation | Pyridine non-classical cannabinoid compounds and related methods of use |
| UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| KR20120060207A (ko) | 2009-08-26 | 2012-06-11 | 사노피 | 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도 |
| UA107088C2 (xx) * | 2009-09-11 | 2014-11-25 | 5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину | |
| RU2012116124A (ru) * | 2009-09-21 | 2013-10-27 | Вандербилт Юниверсити | О-БЕНЗИЛ НИКОТИНАМИДНЫЕ АНАЛОГИ КАК ПОЗИТИВНЫЕ АЛЛОСТЕРИЧЕСКИЕ МОДУЛЯТОРЫ mGluR5 |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| WO2012031817A1 (en) | 2010-09-09 | 2012-03-15 | F. Hoffmann-La Roche Ag | Determination of abca1 protein levels in cells |
| US8410107B2 (en) | 2010-10-15 | 2013-04-02 | Hoffmann-La Roche Inc. | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides |
| US20120101282A1 (en) | 2010-10-22 | 2012-04-26 | Pascal Dott | Process for the preparation of nicotinamide derivatives |
| US8669254B2 (en) * | 2010-12-15 | 2014-03-11 | Hoffman-La Roche Inc. | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US9321727B2 (en) * | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| KR20140061518A (ko) * | 2011-09-12 | 2014-05-21 | 에프. 호프만-라 로슈 아게 | N-(5-사이클로알킬- 또는 5-헤테로사이클릴-)-피리딘-3-일 카복스아마이드 |
| WO2013037703A1 (en) | 2011-09-12 | 2013-03-21 | F. Hoffmann-La Roche Ag | 3 -pyridine carboxylic acid hydrazides as hdl-cholesterol raising agents |
| WO2013037721A1 (en) * | 2011-09-12 | 2013-03-21 | F. Hoffmann-La Roche Ag | 5-cycloalkyl- or 5-heterocyclyl-nicotinamides |
| US9403808B2 (en) * | 2011-10-28 | 2016-08-02 | Hoffmann-La Roche Inc. | Pyrazine derivatives |
| WO2014180741A1 (en) * | 2013-05-06 | 2014-11-13 | F. Hoffmann-La Roche Ag | Methods of identifying modulators of osbpl7 and the use of such modulators for treatment of diseases associated with osbpl7 |
| RU2570907C2 (ru) * | 2013-10-21 | 2015-12-20 | Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" | Производные 3-ациламинопиридин-2(1h)-она, применимые как ингибиторы серин-треониновой протеинкиназы gsk3b в качестве лекарственных препаратов для лечения диабета ii типа. |
| KR102794621B1 (ko) * | 2018-09-04 | 2025-04-14 | 쓰리엠 이노베이티브 프로퍼티즈 캄파니 | 마스크 |
| US11236070B2 (en) | 2019-05-16 | 2022-02-01 | Novartis Ag | Chemical process |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| WO2025172494A1 (en) | 2024-02-16 | 2025-08-21 | F. Hoffmann-La Roche Ag | Novel reversible fluorescent probes for cb1 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US259887A (en) * | 1882-06-20 | Heney mocobb | ||
| US3940418A (en) | 1972-04-07 | 1976-02-24 | G. D. Searle & Co. | Esters and amides of 4,5-dihydrobenz[g]indazole-3-carboxylic acids and related compounds |
| FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| FR2713225B1 (fr) | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
| FR2714057B1 (fr) | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
| GB9405347D0 (en) * | 1994-03-18 | 1994-05-04 | Agrevo Uk Ltd | Fungicides |
| US5596106A (en) | 1994-07-15 | 1997-01-21 | Eli Lilly And Company | Cannabinoid receptor antagonists |
| FR2741621B1 (fr) | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
| DE69822449T2 (de) | 1997-01-21 | 2005-01-27 | Smithkline Beecham Corp. | Neue cannabinoidrezeptor-modulatoren |
| US5948777A (en) | 1997-03-18 | 1999-09-07 | Smithkline Beecham Corporation | Cannabinoid receptor agonists |
| FR2761265B1 (fr) | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates |
| FR2761266B1 (fr) | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates |
| KR100652994B1 (ko) | 1998-09-11 | 2006-11-30 | 아방티 파르마 소시에테 아노님 | 아제티딘 유도체, 이의 제조방법 및 이를 함유하는 약제 |
| FR2783246B1 (fr) | 1998-09-11 | 2000-11-17 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les medicaments les contenant |
| FR2789079B3 (fr) | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
| PL350669A1 (en) | 1999-03-29 | 2003-01-27 | Hoffmann La Roche | Glucokinase activators |
| FR2800375B1 (fr) | 1999-11-03 | 2004-07-23 | Sanofi Synthelabo | Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant |
| US6355631B1 (en) | 2000-03-03 | 2002-03-12 | Aventis Pharma S.A. | Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation |
| FR2805817B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation |
| FR2805810B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation |
| US6566356B2 (en) | 2000-03-03 | 2003-05-20 | Aventis Pharma S.A. | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation |
| US6479479B2 (en) | 2000-03-03 | 2002-11-12 | Aventis Pharma S.A. | Azetidine derivatives, their preparation and pharmaceutical compositions containing them |
| FR2805818B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant |
| DZ3335A1 (fr) | 2000-03-23 | 2001-09-27 | Solvay Pharm Bv | Derives de 4,5-dihydro-1h-pyrazole ayant une activite antagoniste de cb1 |
| TWI259180B (en) * | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
| FR2814678B1 (fr) | 2000-10-04 | 2002-12-20 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite |
| US6509367B1 (en) | 2001-09-22 | 2003-01-21 | Virginia Commonwealth University | Pyrazole cannabinoid agonist and antagonists |
| SE0104332D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| SE0104330D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| EP1492784A4 (de) | 2002-03-28 | 2006-03-29 | Merck & Co Inc | Substituierte 2,3-diphenylpyridine |
| FR2838438A1 (fr) | 2002-04-11 | 2003-10-17 | Sanofi Synthelabo | Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant |
| GB0314057D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| US20040259887A1 (en) | 2003-06-18 | 2004-12-23 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| GB0314049D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| CA2527033A1 (en) | 2003-06-18 | 2004-12-23 | Astrazeneca Ab | 2-substitued 5,6-diaryl-pyrazine derivatives as cb1 modulators |
| GB0314261D0 (en) | 2003-06-19 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| FR2856684B1 (fr) | 2003-06-26 | 2008-04-11 | Sanofi Synthelabo | Derives de diphenylpyridine, leur preparation et leur application en therapeutique |
-
2006
- 2006-03-27 RU RU2007140735/04A patent/RU2404164C2/ru not_active IP Right Cessation
- 2006-03-27 CA CA2602787A patent/CA2602787C/en not_active Expired - Fee Related
- 2006-03-27 WO PCT/EP2006/061060 patent/WO2006106054A1/en not_active Ceased
- 2006-03-27 EP EP06725329A patent/EP1868999B1/de not_active Expired - Lifetime
- 2006-03-27 JP JP2008504738A patent/JP4712865B2/ja not_active Expired - Fee Related
- 2006-03-27 AU AU2006232662A patent/AU2006232662B2/en not_active Ceased
- 2006-03-27 DK DK06725329T patent/DK1868999T3/da active
- 2006-03-27 DE DE602006007563T patent/DE602006007563D1/de not_active Expired - Lifetime
- 2006-03-27 PL PL06725329T patent/PL1868999T3/pl unknown
- 2006-03-27 ES ES06725329T patent/ES2326280T3/es not_active Expired - Lifetime
- 2006-03-27 BR BRPI0609685-9A patent/BRPI0609685A2/pt not_active IP Right Cessation
- 2006-03-27 PT PT06725329T patent/PT1868999E/pt unknown
- 2006-03-27 MX MX2007012213A patent/MX2007012213A/es active IP Right Grant
- 2006-03-27 AT AT06725329T patent/ATE435207T1/de active
- 2006-03-27 KR KR1020077022652A patent/KR100970050B1/ko not_active Expired - Fee Related
- 2006-03-27 CN CN2006800111756A patent/CN101155781B/zh not_active Expired - Fee Related
- 2006-04-03 TW TW095111716A patent/TWI300777B/zh not_active IP Right Cessation
- 2006-04-04 AR ARP060101331A patent/AR054024A1/es not_active Application Discontinuation
- 2006-04-04 US US11/397,743 patent/US7229999B2/en not_active Expired - Fee Related
-
2007
- 2007-09-20 IL IL186126A patent/IL186126A0/en unknown
- 2007-10-04 ZA ZA200708491A patent/ZA200708491B/xx unknown
- 2007-10-09 NO NO20075082A patent/NO20075082L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006232662A1 (en) | 2006-10-12 |
| TWI300777B (en) | 2008-09-11 |
| MX2007012213A (es) | 2007-12-10 |
| PT1868999E (pt) | 2009-08-06 |
| BRPI0609685A2 (pt) | 2010-04-20 |
| AU2006232662B2 (en) | 2011-11-24 |
| JP4712865B2 (ja) | 2011-06-29 |
| CA2602787C (en) | 2013-12-24 |
| US7229999B2 (en) | 2007-06-12 |
| WO2006106054A1 (en) | 2006-10-12 |
| CN101155781A (zh) | 2008-04-02 |
| ZA200708491B (en) | 2008-11-26 |
| EP1868999B1 (de) | 2009-07-01 |
| KR20070110122A (ko) | 2007-11-15 |
| CN101155781B (zh) | 2012-11-07 |
| US20060229326A1 (en) | 2006-10-12 |
| DK1868999T3 (da) | 2009-08-17 |
| RU2007140735A (ru) | 2009-05-20 |
| CA2602787A1 (en) | 2006-10-12 |
| JP2008534648A (ja) | 2008-08-28 |
| KR100970050B1 (ko) | 2010-07-16 |
| ES2326280T3 (es) | 2009-10-06 |
| AR054024A1 (es) | 2007-05-30 |
| RU2404164C2 (ru) | 2010-11-20 |
| PL1868999T3 (pl) | 2009-12-31 |
| NO20075082L (no) | 2007-10-31 |
| IL186126A0 (en) | 2008-01-20 |
| EP1868999A1 (de) | 2007-12-26 |
| TW200640867A (en) | 2006-12-01 |
| DE602006007563D1 (de) | 2009-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE435207T1 (de) | Pyridin-3-carbonsäureamidderivate als cb1-inverse agonisten | |
| LTPA2018501I1 (lt) | Heterocikliniai amido dariniai, naudingi kaip mikrobiocidai | |
| EP4297351C0 (de) | Hash-basiertes multi-homing | |
| DE602006011363D1 (de) | Heteroaryl-substituierte piperidin-derivate als l-cpt1-hemmer | |
| DK1919907T5 (da) | Heterocyklisk forbindelse | |
| ATE517886T1 (de) | Pyrazolderivate | |
| DE602006003575D1 (de) | Schwenkzylinder | |
| ATE530528T1 (de) | N--(3-phenylpropyl)carboxamidderivate als fungizide | |
| ATE509925T1 (de) | Substituierte bicyclocarbonsäureamidverbindungen | |
| ATE420088T1 (de) | Chinolinoncarbonsäureamidverbindungen als 5-ht4- rezeptoragonisten | |
| DE502006000770D1 (de) | Konservierungsmittel | |
| DE602006016566D1 (de) | Als antikoagulanzien verwendbare phenylglycinamid-derivate | |
| EP2189449A4 (de) | Aminopyrazol-amidderivate | |
| ITFI20050094A1 (it) | Opercolatrice perfezionata | |
| EP2119702A4 (de) | Amidderivat | |
| DE602005015204D1 (de) | Oxadiazolonderivate als ppar-delta-agonisten | |
| EP2258697A4 (de) | Hydroxychinoxalincarboxamidderivat | |
| ATE535523T1 (de) | Benzimidazolcarbonsäureamid-verbindungen als 5- ht4 rezeptor-agonisten | |
| DK1931309T3 (da) | Antimykotisk sammensætning | |
| ATE459618T1 (de) | 3-piperidinylisochroman-5-ole als dopaminagonisten | |
| DE502006005182D1 (de) | Heterocyclylamid-substituierte imidazole | |
| DE602006007832D1 (de) | Benzotriazolderivate als cannabinoidrezeptorantagonisten | |
| DE502005004418D1 (de) | Turbolader | |
| EP1867636A4 (de) | Pyridylmethylsulfonderivat | |
| EP1933850A4 (de) | Aptamere als agonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1868999 Country of ref document: EP |
|
| UEP | Publication of translation of european patent specification |
Ref document number: 1868999 Country of ref document: EP |